SI
NBIX icon

Seeds Investor’s Neurocrine Biosciences NBIX Stock Holding History

Seeds Investor’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$322K Sell
2,464
-30
-1% -$3.98K 0.04% 262
2025
Q4 		$354K Buy
2,494
+233
+10% +$33.8K 0.07% 172
2025
Q3 		$317K Buy
2,261
+449
+25% +$60.8K 0.07% 173
2025
Q2 		$228K Buy
+1,812
New +$208K 0.05% 215
2024
Q2 		– Sell
-1,691
Closed -$233K – 223
2024
Q1 		$233K Buy
+1,691
New +$231K 0.21% 137

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seeds Investor's NBIX Position: Q1 2026 in Review

Seeds Investor reduced its Neurocrine Biosciences (NBIX) stake by 1.2% in Q1 2026, selling an estimated $3.98K and leaving 2,464 shares worth $322K. The position accounts for 0.04% of the portfolio, ranked #262.

Seeds Investor first reported a position in NBIX in Q1 2024 and has held it in 5 quarters since. The position peaked at $354K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Seeds Investor held 2,464 shares of Neurocrine Biosciences worth $322K as of Q1 2026.
  • Seeds Investor sold 30 Neurocrine Biosciences shares in Q1 2026, an estimated $3.98K.
  • Neurocrine Biosciences made up 0.04% of Seeds Investor's portfolio in Q1 2026, its #262 holding.
  • Seeds Investor first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 5 quarters since.
  • Seeds Investor's Neurocrine Biosciences position peaked at $354K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Seeds Investor's 13F filing for Q1 2026, filed 11 May 2026.